TNYA insider transaction filings
Tenaya Therapeutics, Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen TNYA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 5,837 @ $0.71 · Sale (S): 3,969 @ $0.71 · Sale (S): 5,020 @ $0.71 · Sale (S): 7,406 @ $0.71 | EDGAR |
| 2026-08-17 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 1,637 @ $0.71 · Sale (S): 1,637 @ $0.71 · Sale (S): 1,871 @ $0.71 · Sale (S): 2,279 @ $0.71 | EDGAR |
| 2026-07-14 | 4 | Hyllengren Eric J — Chief Financial Officer | Grant/award (A): 1,650,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Srivastava Deepak — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Burroughs Amy L. — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Stehman-Breen Catherine — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Lee June — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Parschauer Karah Herdman — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Walsh Jeffrey T. — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Williams R Sanders — Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 3,121 @ $0.79 | EDGAR |
| 2026-05-19 | 4 | Higa Tomohiro — SVP, Finance | Sale (S): 1,485 @ $0.79 | EDGAR |
| 2026-05-19 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 3,390 @ $0.79 | EDGAR |
| 2026-02-26 | 4 | COLUMN GROUP III GP, LP — 10% owner COLUMN GROUP III, LP — 10% owner COLUMN GROUP III-A, LP — 10% owner Column Group Opportunity III, LP — 10% owner Column Group Opportunity III GP, LP — 10% owner TCG Opportunity III GP, LLC — 10% owner Kutzkey Tim — 10% owner Svennilson Peter — 10% owner | Sale (S): 309,228 @ $0.62 · Sale (S): 349,212 @ $0.62 · Sale (S): 1,649,281 @ $0.56 · Sale (S): 1,862,545 @ $0.56 | EDGAR |
| 2026-02-24 | 4 | COLUMN GROUP III GP, LP — 10% owner COLUMN GROUP III, LP — 10% owner COLUMN GROUP III-A, LP — 10% owner Column Group Opportunity III, LP — 10% owner Column Group Opportunity III GP, LP — 10% owner TCG Opportunity III GP, LLC — 10% owner Kutzkey Tim — 10% owner Svennilson Peter — 10% owner | Sale (S): 245,965 @ $0.61 · Sale (S): 277,769 @ $0.61 · Sale (S): 143,709 @ $0.60 · Sale (S): 162,291 @ $0.60 | EDGAR |
| 2026-02-17 | 4 | Higa Tomohiro — SVP, Finance | Sale (S): 611 @ $0.64 · Sale (S): 836 @ $0.64 · Sale (S): 2,022 @ $0.64 | EDGAR |
| 2026-02-17 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 1,642 @ $0.64 · Sale (S): 1,642 @ $0.64 · Sale (S): 1,876 @ $0.64 | EDGAR |
| 2026-02-17 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 5,851 @ $0.64 · Sale (S): 3,979 @ $0.64 · Sale (S): 5,032 @ $0.64 | EDGAR |
| 2026-02-12 | 4 | COLUMN GROUP III GP, LP — 10% owner COLUMN GROUP III, LP — 10% owner COLUMN GROUP III-A, LP — 10% owner Column Group Opportunity III, LP — 10% owner Column Group Opportunity III GP, LP — 10% owner TCG Opportunity III GP, LLC — 10% owner Kutzkey Tim — 10% owner Svennilson Peter — 10% owner | Sale (S): 161,422 @ $0.82 · Sale (S): 182,295 @ $0.82 · Sale (S): 1,905,115 @ $0.68 · Sale (S): 2,151,458 @ $0.68 | EDGAR |
| 2026-02-05 | 4 | Higa Tomohiro — SVP, Finance | Grant/award (A): 29,250 @ $0 · Grant/award (A): 175,500 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Tingley Whittemore — Chief Medical Officer | Grant/award (A): 48,750 @ $0 · Grant/award (A): 318,500 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Ali Faraz — Chief Executive Officer, Director | Grant/award (A): 158,600 @ $0 · Grant/award (A): 952,250 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Higa Tomohiro — SVP, Finance | Sale (S): 1,367 @ $1.33 | EDGAR |
| 2025-11-17 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 2,877 @ $1.33 | EDGAR |
| 2025-11-17 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 3,126 @ $1.33 | EDGAR |
| 2025-08-18 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 1,608 @ $1.25 · Sale (S): 1,608 @ $1.25 · Sale (S): 1,837 @ $1.25 | EDGAR |
| 2025-08-18 | 4 | Higa Tomohiro — SVP, Finance | Sale (S): 523 @ $1.25 · Sale (S): 717 @ $1.25 · Sale (S): 1,722 @ $1.25 | EDGAR |
| 2025-08-18 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 5,720 @ $1.25 · Sale (S): 3,893 @ $1.25 · Sale (S): 4,920 @ $1.25 | EDGAR |
| 2025-05-30 | 4 | Burroughs Amy L. — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Srivastava Deepak — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Stehman-Breen Catherine — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Lee June — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Parschauer Karah Herdman — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Walsh Jeffrey T. — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Williams R Sanders — Director | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | GOEDDEL DAVID V — Director, 10% owner | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Higa Tomohiro — SVP, Finance | Sale (S): 1,390 @ $0.44 | EDGAR |
| 2025-05-16 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 2,937 @ $0.44 | EDGAR |
| 2025-05-16 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 3,189 @ $0.44 | EDGAR |
| 2025-03-10 | 4 | Higa Tomohiro — SVP, Finance | Sale (S): 1,017 @ $0.54 · Sale (S): 620 @ $0.54 · Sale (S): 845 @ $0.54 | EDGAR |
| 2025-03-10 | 4 | Tingley Whittemore — Chief Medical Officer | Sale (S): 1,727 @ $0.54 · Sale (S): 4,073 @ $0.54 · Sale (S): 1,598 @ $0.54 | EDGAR |
| 2025-03-10 | 4 | Ali Faraz — Chief Executive Officer, Director | Sale (S): 5,794 @ $0.54 · Sale (S): 3,947 @ $0.54 | EDGAR |
| 2025-03-07 | 4 | COLUMN GROUP III GP, LP — 10% owner COLUMN GROUP III, LP — 10% owner COLUMN GROUP III-A, LP — 10% owner Column Group Opportunity III, LP — 10% owner Column Group Opportunity III GP, LP — 10% owner TCG Opportunity III GP, LLC — 10% owner | Purchase (P): 35,714,284 @ $0.70 · Purchase (P): 35,714,284 (derivative) · Purchase (P): 17,857,142 (derivative) | EDGAR |
| 2025-03-07 | 4 | GOEDDEL DAVID V — Director, 10% owner | Purchase (P): 35,714,284 @ $0.70 · Purchase (P): 35,714,284 (derivative) · Purchase (P): 17,857,142 (derivative) | EDGAR |
| 2025-02-07 | 4 | Ali Faraz — Chief Executive Officer, Director | Grant/award (A): 107,500 @ $0 · Grant/award (A): 34,424 @ $0 · Grant/award (A): 650,000 (derivative) @ $0 · Disposition to issuer (D): 353,271 (derivative) · Grant/award (A): 353,271 (derivative) · Disposition to issuer (D): 161,214 (derivative) · +3 more | EDGAR |
Recent 8-K events — Tenaya Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-01-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-12-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TNYA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →